Zacks Investment Research upgraded shares of ENDOLOGIX INC (ELGX) from UNDERPERFORM to NEUTRAL on April 30, 2014, with a target price of $12.80.
Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment of atherosclerosis.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on ENDOLOGIX INC (ELGX),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment